Ann: PD-1 cancer vaccine development update, page-73

IMU have taken the decision to release the data of the Her-vaxx trial at its conclusion so they can present the most meaningful and compelling data - they reported in February that things were travelling well and there is no reason to think that is still not the case. Some of the people on this forum are like a little children who need mummy to cuddle them to tell them that she loves them every day - grow up! IMU would be required to disclose to the ASX if the trial was 'tanking' or something negative was occurring. People have to understand that the softer share price we are seeing is the natural consequences of the huge capital raise where a large chunk of stock that was underwritten is being plowed back into the market which has had a flow on effect for other squeamish holders who get nervous and sell. Once that overhang is soaked up we should see more strength returning to the share price. I say if you are worried, get the hell out - don't expect Her-vaxx data until the later end of 2018. Some bright people are seeing this as a great buying opportunity.